News summaryBarron'sOct 14, 2026, 01:46 PM
Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug - Barron's
VSTMhealthcare
Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug Barron's
Loading...
Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug Barron's